Every Form 4 that Immunovant, Inc. (IMVT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMVT filings page.
Immunovant, Inc.’s Chief Technology Officer, Jay S. Stout, reported two direct sales of common stock on October 7, 2026: 2,213 shares and 1,596 shares, each at a weighted average price of $32.06 per share.
The sales were required by Immunovant to cover tax withholding related to RSU vesting and were not discretionary. No Rule 10b5-1 plan is reported.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold 1,327 shares of common stock on October 7, 2026, at a weighted-average price of $32.06 per share; the shares were sold in multiple transactions at prices ranging from $31.58 to $32.30 per share. Immunovant required the sale to cover tax withholding obligations tied to RSU vesting and settlement, so it was not discretionary. After the sale, Van Tuyl directly held 175,218 shares. No Rule 10b5-1 plan is reported.
Immunovant, Inc. (IMVT) Chief Operating Officer Melanie Gloria sold 2,241 shares of common stock on October 7, 2026, at a weighted average price of $32.06 per share. The shares were sold to cover tax withholding tied to 4,761 RSUs that vested October 1, 2026; Immunovant required the sell-to-cover transaction, which was not discretionary. Gloria directly held 217,060 shares afterward.
Immunovant, Inc. Chief Executive Officer Eric Venker reported that 92,187 capped value appreciation rights (CVARs) settled into common stock on October 1, 2026, after the service, performance, knock-in and $14.46 hurdle-price requirements were satisfied. The settlement formula capped the common stock’s fair market value at $16.76 per share. Venker also reported a disposition to the issuer of 85,886 common shares at $33.65 per share and sold 3,506 shares at $34.11 on October 2 to cover tax withholding. The issuer required the sell-to-cover transaction, which was not discretionary; 921,875 CVARs remained after settlement.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold 2,846 shares of common stock on September 23, 2026, at a weighted average price of $36.36 per share, leaving him with 176,545 shares held directly. The sale was a sell-to-cover transaction mandated by the issuer to fund tax withholding tied to the vesting and settlement of 6,872 restricted stock units on September 16, 2026; the transaction was not discretionary. No Rule 10b5-1 plan is reported.
Immunovant, Inc. (IMVT) director Atul Pande exercised fully vested stock options to acquire 1,500 shares of common stock at an exercise price of $8.43 per share and on the same date sold 1,500 shares at $43.27 per share. Following the option exercise, he holds 65,181 options directly, and a separate indirect holding shows 20,000 shares held by a trust. The reported transactions were effected pursuant to a Rule 10b5-1 Plan adopted on December 26, 2025.
Immunovant, Inc. (IMVT) reported that Chief Operating Officer Gloria Melanie sold 3,056 shares of common stock on August 20, 2026, at a weighted average price of $44.16 per share. The shares were sold to cover tax withholding obligations arising from the vesting and settlement of previously granted RSUs under a mandated “sell to cover” arrangement, and are described as not being a discretionary transaction by the officer. Following this sale, she holds 219,301 shares of Immunovant common stock directly.
Immunovant director Atul Pande exercised stock options for 1,500 shares of Common Stock at $8.43 per share and on the same date sold 1,500 shares at $39.80 per share. The option exercise involved a fully vested award and left 66,681 option shares outstanding. In addition, 20,000 Common Shares are held indirectly by a trust. All reported trades occurred under a Rule 10b5-1 trading plan adopted on December 26, 2025.
Immunovant, Inc. Chief Financial Officer Tiago Girao reported the sale of 6,798 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share. The mandated “sell to cover” transaction funded tax withholding on 13,024 vested RSUs, leaving him with 240,798 shares held directly.
Immunovant, Inc. reports that Chief Technology Officer Jay S. Stout sold 2,857 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share, with sale prices ranging from $38.18 to $39.05. The shares were sold to cover tax withholding obligations from the July 17, 2026 vesting of 6,250 restricted stock units from a 100,000-unit grant. After this mandated sell-to-cover transaction, he directly holds 205,341 shares of Immunovant common stock.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported two open-market sales totaling 2,036 shares of common stock on July 8, 2026. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, under a mandated “sell to cover” arrangement rather than a discretionary trade.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported the disposition of 1,206 shares of common stock in open-market sales on July 8, 2026. According to the company’s description, these sales were executed under a mandatory “sell to cover” arrangement to satisfy tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, and were not discretionary trades.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported open-market sales totaling 3,487 shares of common stock on July 8, 2026. According to the footnotes, these trades were mandated “sell to cover” transactions to fund tax withholding triggered by the vesting and settlement of previously granted restricted stock units, rather than discretionary sales.
Immunovant, Inc. Chief Executive Officer Eric Venker reported a compensation-related equity transaction involving capped value appreciation rights (CVARs) and a small tax sale of common stock. On July 1, 2026, 92,188 vested CVARs were settled into shares of common stock after the service, performance, knock-in and hurdle price conditions were met. The same day, a Form 4 entry shows 86,629 shares of common stock disposed to the issuer at $38.14 per share. On July 2, 2026, he sold 3,092 shares of common stock at $38.48 per share in an open-market transaction, which the footnotes state was a mandatory “sell to cover” for tax withholding tied to the CVAR vesting rather than a discretionary sale. After these transactions, Venker directly holds 254,280 shares of Immunovant common stock.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported open-market sales of a total of 17,714 shares of common stock. The shares were sold in two transactions at weighted average prices of $38.18 and $38.95 per share, within disclosed intraday price ranges.
After these sales, she directly holds 224,393 shares of Immunovant common stock, indicating she retains a substantial equity position despite the net reduction.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 40,000 shares of Common Stock in open-market transactions. The sales on June 26, 2026 were executed at weighted average prices of $38.18 and $38.94 per share, with individual trades occurring between $37.74 and $39.13 per share.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported same-day stock option exercises and open-market sales of common stock. He exercised options for 17,824 shares at an exercise price of $15.20 per share and sold 17,824 shares in open-market transactions.
The reported sales were split into 2,842 shares at a weighted average price of $38.96 and 14,982 shares at a weighted average price of $38.19, with actual trade prices ranging from $37.75 to $39.15 per share. Following these transactions, he directly holds 180,597 Immunovant common shares and 53,707 stock options, which expire on April 1, 2035 and vest over time from an April 1, 2025 grant.
Immunovant, Inc. Chief Financial Officer Tiago Girao reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 10,000 shares of Common Stock at a price of $15.90 per share and then sold 10,000 shares in open-market transactions at a weighted average price of $38.46 per share. After these transactions, he directly holds 247,596 Common Shares. The filing notes that the sale was executed in multiple trades between $38.00 and $38.90 per share.
Immunovant, Inc. director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. He exercised 1,500 stock options at $8.43 per share and sold 1,500 common shares at an average price of $38.01 per share pursuant to a Rule 10b5-1 plan adopted on December 26, 2025.
Following these transactions, he holds 116,731 common shares directly, 20,000 common shares indirectly through a trust, and 68,181 stock options (right to buy) remaining.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported an open-market sale of 2,634 shares of common stock at $35.39 per share. This transaction was executed to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units.
According to the disclosure, the sale was mandated by the company’s "sell to cover" election and was not a discretionary trade by the officer. Following the transaction, Van Tuyl directly holds 180,597 shares of Immunovant common stock.
Immunovant director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. On the same day, he exercised options to acquire 1,500 shares of Common Stock at $8.43 per share and sold 1,500 shares in an open-market transaction at $34.02 per share.
The filing shows he continues to hold 116,731 Common Stock shares directly and 20,000 shares indirectly through a trust, as well as 69,681 remaining stock options after the exercise. The transactions were carried out under a Rule 10b5-1 trading plan adopted on December 26, 2025, indicating they were pre-scheduled rather than discretionary.
Immunovant, Inc. director Andrew J. Fromkin reported a combination of option exercises and share sales in common stock. On May 28, 2026, he exercised stock options covering 196,601 shares at strike prices ranging from $4.99 to $14.70 per share, converting derivative awards into common shares.
On the same date, he executed open-market sales totaling 221,951 shares of common stock at weighted average prices of $33.56 and $32.64 per share across multiple trades. Following these transactions, he directly holds 74,382 Immunovant common shares, indicating a net reduction in his direct equity position while retaining a meaningful stake.
Immunovant, Inc.’s Chief Operating Officer, Gloria Melanie, reported selling a total of 3,115 shares of common stock on May 20, 2026 in open-market transactions at prices including $30.41, $32.15, and $32.95 per share. A footnote explains these sales were executed solely to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units granted as part of a larger 109,956 RSU award from November 18, 2024. The issuance’s “sell to cover” structure was chosen by the company and described as a mandated, non-discretionary transaction by the executive. The Form 4 data also reflect a reported direct holding of 244,973 shares of Immunovant common stock after the transactions.
Immunovant, Inc. director Atul Pande reported an option exercise and share sale. On May 20, 2026, he exercised stock options to acquire 6,000 shares of common stock at $8.43 per share and sold 6,000 shares at $32.00 per share.
After these transactions, he directly holds 116,731 common shares and indirectly holds 20,000 shares through a trust. A related footnote states the sale occurred under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was planned in advance.
Immunovant, Inc. director Robert Graham Susman reported an open-market sale of 2,502 shares of common stock at a weighted average price of $27.17 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 30, 2025.
Following this sale, he directly holds 36,394 shares of Immunovant common stock, so the filing reflects a partial reduction rather than an exit from his position.
Immunovant, Inc. Chief Financial Officer Tiago Girao reported an open-market sale of 25,760 shares of common stock at a weighted average price of $29.62 per share. After this transaction, he directly holds 247,596 shares.
According to the footnotes, this sale was executed solely to cover tax withholding obligations tied to the vesting and settlement of 52,097 restricted stock units from a prior grant of 208,388 RSUs. The company required a “sell to cover” transaction, so the sale is described as non-discretionary for the executive.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported an open-market sale of 2,754 shares of common stock at a weighted average price of $29.62 per share. According to the footnotes, these shares were sold solely to cover tax withholding obligations from the vesting of previously granted RSUs.
The sale was mandated by the company’s “sell to cover” election and is described as not a discretionary transaction by the executive. Following the sale, Stout directly owns 251,685 shares of Immunovant common stock.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported an open-market sale of 5,165 shares of common stock on April 8, 2026 at a weighted average price of $24.83 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units and was not a discretionary trade. Following the transaction, Van Tuyl directly holds 183,231 shares of Immunovant common stock.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported an open-market sale of 8,722 shares of common stock at a weighted average price of $24.83 per share. According to the filing, this sale was mandated as a “sell to cover” transaction to satisfy tax withholding obligations from the vesting and settlement of previously granted restricted stock units. On April 1, 2025, she was granted 76,181 RSUs, of which 19,045 RSUs vested on April 1, 2026. Following the sale, she directly holds 245,222 shares of Immunovant common stock.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 10,132 shares of common stock on April 8, 2026, at a weighted average price of $24.83 per share. According to the footnotes, these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units.
The filing states that part of the sale related to 19,045 RSUs that vested on April 1, 2026, from a 76,181-RSU grant made on April 1, 2025, and part related to 3,436 RSUs that vested on April 2, 2026, from a 54,978-RSU grant made on April 2, 2024. After these transactions, Stout directly holds 254,439 shares of Immunovant common stock.
Immunovant, Inc. director Frank Torti reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 88,325 shares of common stock at an exercise price of $24.61 per share, expiring in 2036. He was also granted 174,189 restricted stock units (RSUs), each representing one share of common stock upon vesting. Both the options and RSUs vest in substantially equal quarterly installments over two years starting from April 1, 2026, contingent on his continuous service. Following the common stock award, he directly holds 1,009,228 shares of Immunovant common stock.
Immunovant, Inc. director Andrew J. Fromkin received equity compensation on April 7, 2026. He was granted 13,880 restricted stock units under the 2019 Equity Incentive Plan, with each RSU representing one share of common stock upon vesting.
He was also granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring April 7, 2036. Both the RSUs and options vest in full on April 1, 2027, subject to his continuous service. Following the RSU grant, he holds 99,732 shares of common stock directly, and the RSUs may be settled later if he elects deferral under Rule 409A.
Immunovant, Inc. reported that director Douglas J. Hughes received new equity awards as part of his compensation. He was granted 13,880 shares of Common Stock in the form of restricted stock units, bringing his direct holdings to 134,653 common shares after the grant.
He also received a stock option covering 7,061 shares of Common Stock at an exercise price of $24.61 per share. Both the RSUs and the option awards vest in full on April 1, 2027, subject to his continuous service with the company, and the options expire on April 7, 2036. The RSUs may be settled later at his election, subject to Rule 409A.
Immunovant, Inc. director Atul Pande received new equity awards as part of his compensation. He was granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. He also received 13,880 shares of common stock in the form of restricted stock units. These RSUs and the option shares will vest on April 1, 2027, if he continues service with the company through that date. Following these awards, he holds 116,731 common shares directly and 20,000 common shares indirectly through a trust.
Immunovant, Inc. director Jake Bauer reported receiving new equity awards as part of his compensation. On April 7, 2026 he was granted 13,880 shares of Common Stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in full on April 1, 2027, conditional on his continuous service, and each unit converts into one share, with an option to defer settlement under Rule 409A. He also received a stock option for 7,061 shares at an exercise price of $24.61 per share, expiring April 7, 2036, which will vest on April 1, 2027 on the same service condition. Following the stock grant, he directly owns 38,896 shares of Immunovant common stock.
Immunovant, Inc. director Robert Graham Susman reported equity awards consisting of new stock options and restricted stock units (RSUs). He was granted options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. The shares underlying these options will vest on April 1, 2027, subject to his continuous service. He also received 13,880 RSUs, each representing one share of common stock, which will vest in full on April 1, 2027 under the same service condition. The filing notes he may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Following the RSU grant, he directly owns 38,896 shares of common stock.
Gloria Melanie reported acquisition or exercise transactions in this Form 4 filing.
Immunovant, Inc. Chief Operating Officer Gloria Melanie received new equity awards. On April 7, 2026 she was granted options to buy 121,063 shares of common stock at $24.61 per share, expiring on April 7, 2036, and 83,671 restricted stock units at no cost.
The RSUs vest 25% on April 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments after that date, subject to continued service. The options vest 25% on April 1, 2027, with the balance vesting in thirty-six substantially equal monthly installments, also conditioned on continued service. After these grants, she directly owns 253,944 common shares.
Immunovant, Inc. Chief Technology Officer Jay S. Stout received new equity awards as compensation. He was granted stock options for 96,851 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036, and 66,937 restricted stock units (RSUs).
The RSUs vest as to 25% of the shares on April 1, 2027, with the remaining 75% vesting in twelve successive substantially equal quarterly installments, contingent on continued service. The options vest as to 25% on April 1, 2027, with the balance vesting in thirty-six successive substantially equal monthly installments, also subject to continued service. Following these grants, he directly owns 264,571 shares of common stock.
Immunovant, Inc. granted Chief Legal Officer Christopher Van Tuyl equity awards on April 7, 2026. He received stock options for 59,820 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036.
He was also granted 41,343 restricted stock units (RSUs), each representing one share of common stock. Both the RSUs and the option shares vest as to 25% on April 1, 2027, with the remaining amounts vesting in regular installments thereafter, contingent on his continued service. Following the grant, he directly holds 188,396 shares of common stock.
Immunovant, Inc. Chief Executive Officer Eric Venker received new equity awards as compensation. He was granted stock options covering 336,043 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036.
He also received 232,252 restricted stock units, each representing one share of common stock upon vesting. The options and RSUs vest 25% on April 1, 2027, with the remaining amounts vesting in regular installments thereafter, contingent on his continuous service. Following the RSU grant, he directly holds 251,813 shares of common stock.
Immunovant, Inc. Chief Financial Officer Tiago Girao received new equity awards as part of his compensation. He was granted stock options for 94,002 shares of common stock at an exercise price of $24.61 per share, expiring in 2036, and 64,968 restricted stock units that convert into common shares as they vest.
The RSUs vest 25% on April 1, 2027, with the remainder in 12 quarterly installments, while the options vest 25% on April 1, 2027 and the balance in 36 monthly installments, all contingent on continued service. Following the grant, he holds 273,356 common shares directly.
Immunovant, Inc. Chief Executive Officer Eric Venker reported the vesting and settlement of capped value appreciation rights (CVARs) into 368,750 shares of common stock on April 1, 2026, based on a hurdle price of $14.46 per share. A total of 334,960 shares were then disposed of to the issuer at $25.10 per share, with the remaining shares forming his updated equity position.
On April 2, 2026, Venker sold 12,820 shares at a weighted average price of $24.04 and 1,409 shares at a weighted average price of $24.60. Footnotes state these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations tied to the CVAR settlement and did not represent discretionary trading. Following these transactions, Venker directly holds 19,561 shares of Immunovant common stock.
Immunovant, Inc.’s Chief Legal Officer Christopher Van Tuyl reported a mandated tax-related share sale. On March 18, he disposed of 2,877 shares of common stock at $24.97 per share to cover tax withholding obligations from recently vested restricted stock units. After this transaction, he directly holds 147,053 shares. The company notes this "sell to cover" sale was required under its tax withholding policy and was not a discretionary trade.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported three open-market sales of common stock that together totaled 3,238 shares on February 25, 2026. The reported transactions were executed at weighted average prices of $26.98, $28.16, and $28.90 per share.
According to the footnotes, these shares were sold to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units that vested on February 18, 2026. The filing states that the sales were mandated under a “sell to cover” arrangement and do not represent discretionary trading decisions by the officer.
Immunovant Chief Technology Officer Jay S. Stout reported selling 1,977 shares of common stock at $26.03 per share. After this sale, he beneficially owns 197,634 shares directly.
The filing explains that this sale was not a discretionary trade. It was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. Of an earlier grant of 100,000 RSUs made on April 17, 2023, 6,250 RSUs vested on January 17, 2026, triggering the tax-related sale.
Immunovant, Inc. reported insider share sales by its Chief Technology Officer, Jay Stout, tied to RSU tax withholding. On January 7, 2026, he sold 1,148 shares of common stock at a weighted average price of $26.51 per share and 55 shares at a weighted average price of $26.92 per share. These sales were executed to cover tax withholding obligations from the vesting and settlement of restricted stock units and were mandated by the company’s “sell to cover” election, rather than being discretionary trades. Following the reported transactions, he directly held 199,611 shares of Immunovant common stock.
Immunovant, Inc. (IMVT) reported an insider transaction by its Chief Operating Officer, Melanie Gloria. On November 20, 2025, she sold 10,251 shares of common stock at a weighted average price of $23.54 per share and an additional 2,375 shares at a weighted average price of $23.97 per share.
These sales were made to cover tax withholding obligations related to the vesting and settlement of previously granted restricted stock units, following the company’s required “sell to cover” procedure. After these transactions, she beneficially owned 173,511 shares of Immunovant common stock directly.
Immunovant (IMVT) insider filing: the Chief Medical Officer reported selling 2,595 shares on October 22, 2025 at a weighted average price of $19.03 (range $19.03–$19.20). The sale was a mandated “sell to cover” to satisfy tax withholding tied to the vesting and settlement of RSUs.
After the transaction, the reporting person beneficially owns 217,958 shares. Footnotes note that 6,250 of a previously granted 100,000 RSUs vested on October 17, 2025.
Immunovant, Inc. (IMVT) disclosed an insider transaction by its Chief Technology Officer, Jay Stout. On 10/22/2025, he sold 2,520 shares of common stock at a weighted average price of $19.03 per share, with trades executed between $19.03–$19.23. The filing states this was a mandated “sell to cover” to satisfy tax withholding arising from the vesting and settlement of 6,250 RSUs on 10/17/2025, part of a 100,000 RSU grant awarded on 04/17/2023, and was not a discretionary transaction.
Following the sale, Stout beneficially owned 200,814 shares, held directly.